Trial Profile
Evaluation of efficacy of anti-allergic ophthalmic solution for allergic conjunctival diseases using the allergic conjunctival disease medical treatment assessment system.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2017
Price :
$35
*
At a glance
- Drugs Epinastine (Primary) ; Sodium cromoglicate
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Santen Pharmaceutical
- 21 Feb 2017 Status changed from active, no longer recruiting to completed.
- 19 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.